ASCO2025
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
Advertisement
The three-arm study enrolled patients with disease refractory to prior carfilzomib, daratumumab, or pomalidomide therapy.
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
AI is revolutionizing oncology with faster analysis, better predictions, and more personalized cancer care.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Peripheral blood samples were analyzed within a phase 2 trial of this bispecific antibody as 1L treatment for FL and MZL.
Ibrutinib plus venetoclax shows strong CR rates and durable remissions in older and younger MCL patients with TP53 mutations.
Zanubrutinib and venetoclax show deep and lasting responses in frontline CLL and SLL including those with del 17p or TP53.
A fixed duration regimen of the combination was compared with a regimen guided by measurable residual disease.
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
Dr. Andorsky discusses CML dose escalation, treatment discontinuation, and unmet needs in leukemia care.
Frontline luspatercept demonstrates superior efficacy compared with ESAs in patients with lower-risk MDS.
100% MRD-negative CR in Ph+ ALL? Dr. Catherine Lai recaps standout abstracts from an ASCO rapid oral session.
The median progression-free survival was 33.2 months in the BVd arm, compared with 11.1 months in the DVd arm.
Naval Daver, MD, presented on the efficacy and safety of bexmarilimab plus standard-of-care azacitidine for MDS at ASCO 2025.
Dr. Tam reviews 5-year data from SEQUOIA showing strong efficacy of zanubrutinib in older CLL patients with 17p deletion.
Belantamab mafodotin plus pomalidomide-dexamethasone showed greater efficacy to pomalidomide-bortezomib-dexamethasone.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.